Research on Alzheimer's disease, from early signs to new therapies. Covers screening tools, brain damage mechanisms, risk factors, sleep, and drug targets.
Scientists have successfully imaged superspreader fibrils in the brain tissue of Alzheimer's patients, shedding light on their role in spreading the disease. The study, published in Science Advances, uses advanced imaging techniques to visualize the fibrils' formation and spread.
Dr. Joongkyu Park has been awarded two new NIH grants totaling $2.3 million to investigate local protein synthesis in tau pathology neurodegeneration and redirected CaMKII for restoring deficits in Alzheimer's disease models. The research aims to understand how these mechanisms contribute to the pathologic features of Alzheimer's disease.
Researchers found that patients taking semaglutide had a significantly lower risk of developing Alzheimer's disease compared to those on other anti-diabetic medications. The study suggests potential benefits for preventing neurodegeneration and neuroinflammation.
A study by FSU researchers has found a potential link between an infection caused by gut bacteria and the progression of Alzheimer's disease. The research suggests that antibiotic exposure can lead to issues not just in the gut but also in the brain, triggering neuroinflammation and neurocognitive impairment.
A new study by MIT scholars finds that hospice care generates substantial savings for the US Medicare system, with $29,000 in cost savings over five years for patients with Alzheimer's Disease. Hospice care provides palliative-type care at a lower cost than elaborate medical procedures, saving lives and reducing suffering.
Researchers have uncovered a new mechanism in the growth of amyloid β (Aβ) fibrils, which are closely associated with Alzheimer's disease. The team found that each Aβ fibril is composed of two thin strands called protofilaments, and when their ends align, the fibril enters a paused state where growth temporarily stops.
Researchers have unveiled a complex interplay between liver X and thyroid hormone receptors that regulates critical brain functions and protects against neurodegeneration. LXRs play a crucial role in regulating thyroid hormone function in the brain, while both receptors are essential for normal brain development and maintenance.
Mass General Brigham has been awarded $3.29 million by ARPA-H to develop a wearable device that monitors the brain's glymphatic system during sleep, which may lead to early detection of neurodegenerative diseases like Alzheimer's in women. The project aims to create a tool for personalized interventions and make it widely accessible.
A new Concordia study reveals that bilingualism is associated with larger and healthier hippocampi in patients with Alzheimer’s disease. The research found no evidence of hippocampal atrophy in bilinguals across the continuum of Alzheimer’s development.
A new study found that 3% of people with traditional Medicare switch to Medicare Advantage each year, but many switch back after a short period. The researchers discovered that people who switched from MA to traditional Medicare were more likely to choose higher-rated plans or those with broader networks.
A team of researchers has developed an AI-powered system to provide evidence-based caregiver training information and support to individuals with Alzheimer's and related dementia. The system is designed to be personalized and accessible, using validated resources and tools to address the unique needs of caregivers.
Scientists have identified a key driver of brain inflammation in neurological diseases, proposing a new treatment approach by neutralizing fibrin. This protein, involved in blood coagulation, triggers neurologic diseases by hijacking the immune system, resulting in damaged neurons.
Researchers at ETH Zurich have developed a method to study protein interactions using LiP mass spectrometry, identifying thousands of interaction interfaces between proteins. They found that stress situations alter around five dozen protein complexes and their interactions, with a key player being the SAGA complex.
Researchers found TBI increases hyperphosphorylated tau, astro- and microgliosis, synaptic dysfunction and cognitive impairments linked to developing Alzheimer’s. BAG3 overexpression ameliorates tau hyperphosphorylation, synaptic dysfunction and cognitive deficits through the enhancement of the autophagy-lysosome pathway.
Researchers analyzed 84 brains to find that the first phase of Alzheimer's disease damages a specific type of inhibitory neuron, triggering neural circuit problems. The study confirms previous findings and identifies new changes during the disease.
A new study suggests that introducing a smaller vial size for the Alzheimer's drug lecanemab could reduce waste by 74% and save Medicare up to $336 million per year. This is due to the high amount of unused medication being discarded, with each patient often receiving a dose lower than the available vial sizes.
Researchers aim to develop small molecule drugs to target neuroinflammation in the brain, which contributes to cognitive decline. The goal is to slow or even cure Alzheimer's disease, offering a potential game-changer for the therapeutic landscape.
Researchers created a detailed picture of how Alzheimer's disease progresses at the cellular level, identifying specific neurons lost to the disease and potential targets for new treatments. The study analyzed over 3.4 million cells from 84 brains, providing a high-resolution view of AD impacts on different cell populations over time.
A new study found that HDL particle quality declines over time in women after menopause, increasing risk of episodic memory loss. Women with smaller, more functional HDL particles are less likely to experience cognitive decline.
Researchers at Indiana University are developing next-generation ophthalmoscopes to spot early warning signs of diseases like Alzheimer's, diabetes, and heart disease with a simple eye scan. The technology uses machine learning and AI to reduce diagnosis time from days to minutes.
Brain cells called OPCs (oligodendrocyte precursor cells) play a crucial role in shaping neural circuitry by pruning unnecessary synapses. This process is essential for the brain's functioning and has been linked to both glioma brain cancer and Alzheimer's disease.
Researchers validate a new blood test platform that can measure multiple biomarkers of Alzheimer's disease, potentially improving early diagnostics and treatment. The platform captures changes in proteins related to neurodegenerative diseases and may help track disease progression over time.
A new supplement celebrating the 100th volume of the Journal of Alzheimer’s Disease presents insights into the state of art in AD research. Recent advancements in geroscience have led to the development of preventive medical strategies targeting aging, holding promise for reducing disease risk.
A recent study found that tau protein buildup disrupts the salience network, a crucial communication network in the brain, leading to behavioral changes. The study used advanced medical imaging to analyze the brains of 128 people with early-stage dementia and showed a strong association between tau disruption and behavioral symptoms.
Researchers have developed a peptide inhibitor called RI-AG03 that effectively prevents Tau protein aggregation in lab and fruit fly studies. The breakthrough targets both major aggregation-promoting 'hotspots' of the Tau protein, potentially paving the way for more effective treatments for neurodegenerative diseases.
University of Rochester researchers have refined a noninvasive method called BL-OG that harnesses light to activate neurons in the brain. The technique has the potential to transform invasive procedures used to treat Parkinson's disease and other neurological conditions by providing a safer, less invasive alternative.
Researchers have developed a promising new drug, RI-AG03, that successfully targets and blocks both major aggregation-promoting 'hotspots' of the Tau protein. The peptide-based approach shows significant potential in preventing the build-up of Tau proteins and neurodegeneration, addressing a critical gap in current treatments.
Researchers at NYU Langone Health will use visible-light OCT technology to detect biomarkers of neurodegenerative disease, including Alzheimer’s and Parkinson’s diseases. The study aims to identify retinal layers and monitor the effects of therapies.
A new clinical trial reveals that synthetic cannabis, specifically dronabinol, can effectively reduce agitation in patients with Alzheimer's disease by an average of 30%. The treatment showed similar calming effects to current medications without adverse results such as delirium or seizures.
Researchers from Brigham and Women's Hospital found that older adults who sustained a traumatic injury were more likely to be diagnosed with Alzheimer's disease and related dementias if they experienced falls. The study suggests that completing cognitive screenings in older patients after a fall could help detect dementia sooner.
Researchers found that combining APOE4 and TREM2 variants triggers inflammatory response in female brains, damaging brain regions involved in thinking and memory. This study emphasizes the need for tailored approaches to treat Alzheimer's disease differently in men and women.
A research team led by Maria Glymour will investigate four modifiable risk factors for ADRD: lifetime alcohol use, depression, vision and hearing impairments, and social isolation. The project aims to provide comprehensive evidence on how these risk factors contribute to ADRD risk.
Researchers discovered phytoene boosts nematode lifespan by 10-18.6% and reduces amyloid plaque formation by 30-40%. The study uses Caenorhabditis elegans as a model organism.
An investigation by The BMJ raises concerns about the safety and effectiveness of donanemab, a new Alzheimer's drug approved by the US FDA. Financial ties among expert advisors have sparked doubts about the drug's reliability.
UTHealth Houston researchers are exploring new pathways to treat Alzheimer's disease through multiple projects funded by the Texas Alzheimer's Research and Care Consortium. Studies aim to investigate ACSL4 gene, delirium's impact on disease progression, biological aging, and noninvasive diagnosis methods.
A new study found that amyloid-beta and tau proteins affect brain activity differently, with increased levels leading to hyperactivity and decreased levels resulting in hypoactivity. Participants with higher rates of this brain slowing showed greater cognitive decline in attention and memory.
Researchers discovered microRNA biomarkers that can diagnose mild cognitive impairment and predict dementia conversion, offering a novel blood test for early detection. The findings provide insights into molecular mechanisms driving the disease and may inform therapeutic targets.
ASU has created an Edward R. Roybal Center to develop and adapt technology-enabled lifestyle and behavioral interventions for older adults with cognitive decline. The center aims to help individuals maintain independence while managing challenges of aging.
A new study by UT Health San Antonio found that higher levels of leptin are associated with better signal-transmitting brain white matter in middle-aged adults. The researchers also discovered a link between leptin bioavailability and reduced risk of cognitive impairment, providing potential insights into obesity's role in dementia.
Researchers identified known genetic variants for Alzheimer’s disease as risk factors for all-cause dementia and vascular dementia. The study also found a substantial genetic overlap with vascular dementia and cerebral small-vessel disease.
The Mount Sinai Health System is deploying blood-based biomarkers and confirmatory tests for Alzheimer's disease and related dementias, enabling early detection and intervention. The system aims to stratify patients rapidly, non-invasively, and cost-effectively.
Scientists have developed new therapies that selectively remove aggregated tau proteins associated with Alzheimer's disease in mice. The approach utilises TRIM21 to target tau aggregates, leaving healthy tau intact, and demonstrates potential for other brain disorders driven by protein aggregation.
Researchers have developed a new diagnostic algorithm using positron emission tomography (PET) to distinguish between Alzheimer's disease and primary tauopathy. The biomarkers enable doctors to identify the presence of a 4-repeat tauopathy with high accuracy, facilitating earlier diagnosis and personalized treatment strategies.
A recent study presented at the Future of Dementia in Africa conference reveals genetic differences between African and Caucasian populations with Alzheimer's disease. The findings suggest that a lack of diversity in genomic studies may limit the effectiveness of targeted therapies across diverse populations.
A study published in the journal Brain shows that increases in protein levels with new Alzheimer's drugs can explain the slowing of cognitive impairment at least as well as the reduction in amyloid plaques. The researchers found that higher levels of a critical brain protein correlate equally well with cognitive benefits.
New research from Rush University Medical Center finds an association between outdoor light exposure at night and Alzheimer's disease prevalence in those under 65. The study suggests that higher nighttime light intensity may disrupt the body's natural sleep-wake pattern, leading to increased inflammation and disease risk.
A $3.9 million grant from the National Institutes of Health supports a study on wearable sleep trackers and AI in predicting blood biomarkers of Alzheimer's disease in at-risk individuals. The research aims to create an 'early warning system' for flagging individuals with a genetic predisposition to Alzheimer's.
Researchers have discovered a potential treatment for traumatic brain injury (TBI) that prevents chronic neurodegeneration by targeting mitochondrial fission. P110, a small peptide agent, has been shown to halt the process and protect the brain from damage.
A new study finds that greater trauma exposure, particularly sexual trauma, is associated with markers of accelerated brain age and neuroinflammation. Women, especially Black women, are at a higher risk of brain aging and Alzheimer's disease due to trauma exposure.
The UW Medicine program aims to improve the detection and management of Alzheimer’s disease and other dementias among American Indian and Alaska Native elders. Trainees will learn to recognize early symptoms, manage dementia locally, and promote culturally appropriate community outreach.
A new study reveals a significant correlation between entorhinal cortex thickness and financial exploitation vulnerability, a potential early indicator of Alzheimer's disease. The research suggests that assessing financial awareness could help identify cognitive changes in older adults.
Research found a positive association between outdoor nighttime light pollution and Alzheimer's disease prevalence, particularly in those under 65. Higher light intensity was associated with greater AD prevalence in this age group, suggesting they may be more vulnerable to the effects of light exposure.
Researchers have developed an integrated optical sensor capable of detecting dopamine directly from unprocessed blood samples. This breakthrough enables low-cost and efficient screening tools for various neurological conditions and cancers.
A Trinity scientist has won an ERC Starting Grant to investigate the role of microglia in brain disorders. The project aims to create a detailed map of how these immune cells change during brain damage, disease, or repair, with the goal of developing methods to control and rejuvenate neuropathology.
A new narrow-spectrum antibiotic, FP 100, has been found to effectively eliminate Fusobacterium nucleatum without harming the oral or gut microbiomes. This breakthrough discovery holds significant implications for treating severe gum disease and preventing related systemic conditions such as colon cancer and Alzheimer's disease.
Researchers have identified a unique biomarker in human blood serum that shows potential for early diagnosis of Alzheimer's disease. The study's findings suggest that this test could be used to diagnose AD before cognitive decline or symptoms become apparent, enabling earlier lifestyle changes and medication to slow disease progression.
A study published in The EMBO Journal reveals that PQBP3 plays a crucial role in stabilizing the nuclear membrane, which is destabilized in senescent cells and contributes to neurodegenerative disorders. PQBP3's dysfunction may lead to the degradation of Lamin B1, a protein essential for maintaining the nuclear membrane.
Researchers have developed a cost-effective and easily reproducible point-of-care testing device that can accurately measure cortisol levels in the blood. The device uses iridium oxide nanoparticles to improve stability, sensitivity, and selectivity, allowing for commercial use.
A study by Baylor College of Medicine researchers reveals that Tau protein mitigates neuronal damage caused by reactive oxygen species and promotes healthy aging. The findings support a new neuroprotective role for Tau against the toxicity associated with ROS.
Researchers mapped 1.65 million cells from 437 aging brains, identifying two distinct paths of cellular change that lead to either Alzheimer's disease or alternative brain aging. These findings offer new insights into the development of Alzheimer's and how it differs from healthy brain aging.